Contraceptive Technology Update – January 1, 2017
January 1, 2017
View Issues
-
STDs at Unprecedented High in United States
Public health agencies battle rise in midst of budget cuts.
-
Data Support Five-year Use of Liletta
Data from a recent analysis of the 52 mg levonorgestrel Liletta intrauterine device indicate its calculated levonorgestrel content and release rate curves support the continued evaluation of its contraceptive use for five or more years.
-
Check Reproductive Health Considerations for Women Presenting with Rheumatoid Arthritis
Women diagnosed with rheumatoid arthritis must consider their drug treatment when choosing a contraceptive. Current treatment practice is to prescribe non-biologic disease-modifying antirheumatic drugs, which reduce disease activity and prevent joint deformity, within three months of diagnosis.
-
Data Indicate Male Birth Control Shot May Be Effective
Men may be able to use birth control shots to prevent pregnancy in their female partners, data suggest in a just-published Phase II study.
-
Link Between Early Menopause, Higher Risk of Fracture Confirmed
A new analysis of data from the Women’s Health Initiative trial indicates an increased risk of fracture among women who reported early menopause (age 40 or younger), regardless of whether they were treated with hormone therapy and/or calcium and vitamin D supplementation.
-
Just Two HPV Shots Recommended for Younger Teens
The CDC now recommends that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart, rather than the previously recommended three doses.